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and December 2014 were retrospectively reviewed.
Results: Of 105 HSCT recipients included in this study, 55 (52.4%) received an allo-HSCT and 50
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duration were associated with bacteremia in allo- and auto-HSCT recipients (p Z 0.001 and
pZ 0.002, respectively). Auto-HSCT recipients with bacteremia had a longer hospital stay after
transplantation, while allo-HSCT recipients with bacteremia had an increased 45-day mortality
rate as compared with those without bacteremia (pZ 0.014 and pZ 0.013, respectively). All 14
Gram-negative blood isolates in this study were resistant to fluoroquinolone.
Conclusion: Levofloxacin prophylaxis in HSCT recipients is associated with the emergence of
fluoroquinolone-resistant Gram-negative bacteria. The risk factors and clinical outcomes of
bacteremia differ between allo- and auto-HSCT recipients, and these differences should be
taken into account when designing strategies to prevent bacteremia.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
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Bacteremia is a common infectious complication in patients
undergoing hematopoietic stem cell transplantation (HSCT),
with an incidence that ranges from18.6% to 43.6%, depending
on study design, population, and transplantation protocol
used.1e5 When bacteremia occurs in HSCT recipients, it is
associatedwith increasedmorbidityandmortality.4,6e8 Based
on evidence that antibiotic prophylaxis improves clinical
outcomes in patients with neutropenia after chemotherapy,
the use of prophylactic antibiotics was recommended for
allogeneic and autologous HSCT (allo-HSCT and auto-HSCT)
recipients.9,10 A recent meta-analysis of HSCT recipients
showed that primary prophylaxis with antibiotics reduced the
incidence of bacteremia as compared with no prophylaxis.11
Despite the clinical benefits of primary antibiotic prophy-
laxis in HSCT recipients, concerns remain over the possible
increase in antibiotic resistance.12e15
In Taiwan, most centers used fluoroquinolone for bac-
terial prophylaxis in HSCT recipients as recommended.
Previous studies on the experience of fluoroquinolone pro-
phylaxis in HSCT recipients in Taiwan focused mostly on
allo-HSCT recipients.16e18 Information concerning fluo-
roquinolone prophylaxis in auto-HSCT recipients has not yet
been reported. Our institution has used levofloxacin for
primary bacterial prophylaxis during the neutropenic phase
in auto-HSCT and allo-HSCT recipients since January 2003.
Initially, we used a dose of 500 mg/day; however, based on
evidence that a higher dose of levofloxacin (750 mg/day)
exhibited better antibacterial activity against Pseudomonas
spp. and similar tolerance rates as compared with a lower
dose of levofloxacin (500 mg/day), we shifted to a higher
dose of levofloxacin (750 mg/day) in January 2011.19
The purpose of this study was to compare the risk factors
and clinical outcomes of patients with bacteremia accord-
ing to the type of HSCT received and following levofloxacin
prophylaxis after transplantation and analyze resistant
patterns of blood isolates.
Methods
Study design
A retrospective chart review was conducted at the Tri-
Service General Hospital, National Defense Medical Center,ang C-H, et al., Characteristics
ts with levofloxacin prophylaxis
016), http://dx.doi.org/10.1016/which is a 1700-bed teaching hospital in Taiwan. Patients
18 years of age that had received an allo-HSCT or auto-
HSCT between January 2005 and December 2014, and had
received levofloxacin for primary bacterial prophylaxis
during the peritransplantation period, were included in this
study. Patients who had received more than one HSCT were
treated as multiple patients for the purpose of this study.
The clinical characteristics, outcomes, and microbiological
data of blood isolates from patients were retrieved by
reviewing their medical charts. This study was approved by
the Institutional Review Board of the hospital (TSGHIRB
approval number: 1-103-05-015).
Transplantation environment and supportive care
All patients receiving a transplant stayed in the trans-
plantation unit of the hospital, which consists of a
specialized single room with the standard protective envi-
ronment. The transplantation unit was equipped with high-
efficiency particulate air filters and reverse-osmosis water
systems for a clean water supply. Other protective mea-
sures in the unit included standard precautions for health-
care workers and low microbial-content diets.
The patients were implanted with a Hickman catheter
before initiating the conditioning regimen for drug infusion
andparental nutrition.Granulocytecolony-stimulating factor
was transfused from the day of transplant until engraftment.
Patients were advised to gargle with a 0.2% chlorhexidine
gluconate solution twice a day from the start of conditioning
chemotherapy for oral hygiene and to continue until the
mucositiswas resolved. The transplantationprotocol for each
patient was reviewed and approved by the cancer committee
in our institution before the transplant.
Infection prophylaxis and management
All patients received acyclovir for antiviral prophylaxis
from the start of conditioning until engraftment. Auto-
HSCT recipients received oral fluconazole tablets, while
allo-HSCT recipients received oral fluconazole tablets (from
January 2005 to June 2011) or an oral suspension of pos-
aconazole (from July 2011 to Dec 2014) for antifungal
prophylaxis. Both allo-HSCT and auto-HSCT recipients were
given oral levofloxacin for bacterial prophylaxis, at a dose
of 500 mg/day from January 2005 to December 2010, andcomparisons of bacteremia in allogeneic and autologous hemato-
and influence on resistant bacteria emergence, Journal of Micro-
j.jmii.2016.02.003
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duration of antifungal and antibacterial prophylaxis in allo-
and auto-HSCT recipients was the same as that used for the
antiviral prophylaxis.
Neutropenic fever was defined as an oral temperature
>38.3C and an absolute neutrophil count <500/mL. When
febrile neutropenia occurred in patients, chest radiography
was performed, and urine, sputum, and blood were sent for
culture. High-resolution computed tomography (CT) of the
thorax was performed if the chest X-ray findings or clinical
presentations were suggestive of an invasive fungal infec-
tion. Abdominal sonography or CT was performed if clinical
symptoms and signs were suggestive of an abdominal
infection. The initial prophylactic antibiotics were dis-
continued, and broad spectrum antibiotics were given
empirically after a thorough assessment by an infectious-
disease specialist in accordance with guidelines of the In-
fectious Diseases Society of America and Taiwan.20,21 A
parenteral broad-spectrum antifungal agent was also
administered empirically if clinical characteristics sug-
gested an invasive fungal infection in febrile patients after
being assessed by two different infectious-disease special-
ists and a hematologist. Tests for galactomannan and
(1e3)-b-D-glucan were not available during the study
period.Definitions and data collection
Early infections recorded in our study were defined as
infection episodes occurring during the pre-engraftment
risk period defined as 45 days after transplantation.22 Early
mortality was defined as death within 45 days after trans-
plantation. Cause of death was recorded according to the
coding on the medical records as primary cause of death.
Infection episodes occurring during this period and related
clinical information in patients were retrieved via medical
chart review. Engraftment was defined as an absolute
neutrophil count >500/mL after the nadir absolute count.
Bacteremia was defined as a recognized pathogen cultured
from one or more blood cultures, or cultured from two or
more blood cultures drawn on separate occasions, with
signs of sepsis if a common skin contaminant (i.e., diph-
theroids, Bacillus spp., Propionibacterium spp., coagulase-
negative staphylococci, viridians group streptococci, Aer-
ococcus spp., or Micrococcus spp.) was identified. In-
fections other than bacteremia were recorded according to
Centers for Disease Control definition of health care-
associated infections.23 Invasive fungal infections were
classified as possible, probable, or proven, based on the
2008 criteria of the European Organization for Research and
Treatment of Cancer.24 Cytomegalovirus (CMV) end-organ
disease was defined as the isolation of CMV or detection
of viral proteins or nucleic acids in tissue specimens, along
with associated symptoms and signs.25 Blood isolates were
not preserved in our hospital; therefore, we retrospectively
reviewed positive blood-culture reports and reassessed
antibiotic sensitivity according to the Clinical Laboratory
Standards Institute 2013 criteria.26 In this study, ciproflox-
acin sensitivity was used as an indicator of fluoroquinolone
sensitivity in Gram-negative bacteria, and levofloxacin and
moxifloxacin sensitivity was used as an indicator ofPlease cite this article in press as: Wang C-H, et al., Characteristics
poietic stem cell-transplant recipients with levofloxacin prophylaxis a
biology, Immunology and Infection (2016), http://dx.doi.org/10.1016/fluoroquinolone sensitivity in Streptococcus spp. and
Staphylococcus spp., respectively. Multiple-drug resistance
in Gram-negative bacteria was defined as resistance to
more than three classes of antibiotics.27
Statistical analysis
Data were stratified on the basis of HSCT type and presence
or absence of bacteremia. Data were compared between
allo- and auto-HSCT recipients using SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA). Categorical variables were analyzed
with the Chi-square or Fisher’s exact test, as appropriate,
and continuous variables were analyzed with the Mann-
Whitney U test. All p-values were 2-tailed, and a p < 0.05
was considered statistically significant.
Results
Patient characteristics
During the study period, 111 patients underwent HSCT at
our institution. Three patients <18 years of age were
excluded, and another three patients were excluded,
because they did not receive levofloxacin for bacterial
prophylaxis. Therefore, a total of 105 patients were
included in this analysis. Of these 105 patients, 55 under-
went allo-HSCT and 50 underwent auto-HSCT.
The median age of allo-HSCT recipients was less than
auto-HSCT recipients (30 years vs. 42 years, p < 0.001). The
most common hematological disease in allo- HSCT and auto-
HSCT recipients was acute myeloid leukemia and lym-
phoma. Among patients receiving auto-HSCT recipients
with lymphoma and leukemia (n Z 35), 19 (54.3%) were in
complete remission at transplant. In allo-HSCT recipients
with leukemia and lymphoma (n Z 42), 18 (42.8%) were in
complete remission. The median cycles of chemotherapy
within 6 months before transplantation in allo- HSCT and
auto-HSCT recipients were 3 (range: 0e6) and 2.5 (range:
0e16), respectively. The duration of engraftment was
longer in allo-HSCT recipients as compared with auto-HSCT
recipients (17 days vs. 12 days, p < 0.001). Allo-HSCT re-
cipients had a higher early mortality rate (12.7% vs. 4.0%,
p Z 0.165) relative to auto-HSCT recipients, but signifi-
cance for this finding was not observed.
Early infectious complications in allo- and auto-
HSCT recipients
One hundred and seventeen infectious episodes occurred in
95 recipients during the early-risk period, with 69 and 48
episodes in allo- and auto-HSCT recipients, respectively.
The most frequent diagnosis was fever of unknown origin
(n Z 47, 40.2%), followed by bacteremia (n Z 28, 23.9%)
and lower respiratory tract infection (nZ 25, 21.4%). Other
infections included oral cavity infection (nZ 6, 5.2%), soft-
tissue infection (n Z 4, 3.5%), urinary tract infection
(n Z 2, 1.6%), and gastrointestinal tract infection (n Z 1,
0.8%). Additionally, two invasive fungal infections and two
CMV end-organ diseases were also noted. Among patients
with infection (n Z 95), 11/95 (11.5%) patients sufferedcomparisons of bacteremia in allogeneic and autologous hemato-
nd influence on resistant bacteria emergence, Journal of Micro-
j.jmii.2016.02.003
4 C.-H. Wang et al.
+ MODELfrom septic shock when infection occurred. Early mortality
in allo- and autoeHSCT recipients was 12.7% and 4%,
respectively. Among allo-HSCT recipients who died in the
early period (n Z 7), five deaths were attributed toTable 1 Transplantation characteristics and outcomes of patie
Outcome
Allo-HSCT (n Z 55)
Bacteremia No bacteremia pa A
Number of
patients, n (%)
15 (27.2) 40 (72.8) 5
Age, y b 30 (18e60) 30.5 (18e62) 0.798 3
Male gender, n (%) 9 (60.0) 30 (75.0) 0.326 3
Primary diagnosis,
n (%)
Lymphoma 0 (0.0) 3 (7.5)
Aplastic anemia 2 (13.3) 5 (12.5)
Acute myeloid
leukemia
5 (33.3) 15 (37.5) 2
Acute lymphoblastic
leukemia
7 (46.6) 12 (30.0) 1
Myelodysplastic
syndrome
1 (6.6) 2 (5.00)
Chronic myeloid
leukemia
0 (0.0) 3 (7.5)
Multiple myeloma 0 (0.0) 0 (0.0)
Donor type, n (%)
MUD 5 (33.3) 19 (47.5) 2
MMUD 2 (13.3) 4 (10.0)
MFD 8 (53.3) 17 (42.5) 2
Stem cell source,
n (%)
Peripheral blood 15 (100.0) 38 (95.0) >0.99 5
Umbilical cord blood 0 (0.0) 2 (5.0)
Total body irradiation,
n (%)
3 (20) 15 (38.5) 0.197 1
Condition regimen,
n (%)
Myeloablative 10 (66.7) 28 (70.0) >0.99 3
Reduced intensity 5 (33.3) 12 (30.0) 1
GVHD prophylaxis,
n (%)
Methotrexate þ
cyclosporine
9 (60.0) 19 (47.5) 0.409 2
Methotrexate þ
cyclosporine þ ATG
6 (40.0) 21 (52.5) 2
Acute GVHD, n (%)
Grade 3e4 6 (40.0) 1 (2.5) 0.001
Grade 0e2 9 (60.0) 39 (97.5) 4
Engraftment duration b 18 (12e31) 17 (13e29) 0.494 1
High dose levofloxacin
prophylaxis, n (%)
6 (40.0) 15 (37.5) >0.99 2
Early mortality, n (%) 5 (33.3) 2 (5.0) 0.013
Hospital stay after
HSCT in survivalsb
39 (20e94) 32 (22e101) 0.257 3
a For comparison of the patients with and without bacteremia in a
b Data are presented as medians (range).
Allo-HSCT Z allogeneic hematopoietic stem cell transplantation; AT
poietic stem cell transplantation; GVHD Z graft-versus-host
MFD Z mismatched family donor; MMUD Z mismatched unrelated do
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biology, Immunology and Infection (2016), http://dx.doi.org/10.1016/bacteremia, one to lower respiratory tract infection, and
one pulmonary hemorrhage. Among early mortality cases in
auto-HSCT recipients (n Z 2), one died of bacteremia and
the other of lower respiratory tract infection.nts receiving HSCT with bacteremia.
Characteristic
Auto-HSCT (n Z 50)
ll Bacteremia No bacteremia pa All
5 (100.0) 10 (20.0) 40 (80.0) 50 (100.0)
0 (18e62) 38 (21e67) 44 (18e63) 0.752 42 (18e67)
9 (70.9) 6 (60.0) 23 (57.5) >0.99 28 (56.0)
3 (5.4) 8 (80.0) 23 (57.5) 31 (62.0)
7 (12.7) 0 (0.0) 0 (0.0) 0 (0.0)
0 (36.3) 0 (0.0) 4 (10.0) 4 (8.0)
9 (34.5) 0 (0.0) 0 (0.0) 0 (0.0)
3 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
3 (5.4) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 2 (20.0) 13 (32.5) 15 (30.0)
4 (43.6)
6 (10.9)
5 (45.4)
3 (96.4)
2 (3.6)
8 (32.7)
8 (69.0) 10 (100.0) 40 (100.0) 50 (100.0)
7 (30.9) 0 (0.0) 0 (0.0) 0 (0.0)
8 (50.9)
7 (49.1)
7 (12.7)
8 (87.2)
7 (12e31) 15 (11e20) 12 (9e26) 0.002 12 (9e26)
1 (38.1) 4 (40.0) 21 (52.5.) 0.725 25 (50.0)
7 (12.7) 1 (10.0) 1 (2.5) 0.363 2 (4.0)
3 (20e101) 25 (20e50) 21 (12e74) 0.014 23 (12e74)
llo-HSCT and auto-HSCT groups, respectively.
G Z antithymocyte globulin; Auto-HSCT Z autologous hemato-
disease; HSCT Z hematopoietic stem cell transplantation;
nor; MUD Z matched unrelated donor.
comparisons of bacteremia in allogeneic and autologous hemato-
and influence on resistant bacteria emergence, Journal of Micro-
j.jmii.2016.02.003
2 Blood isolates from HSCT recipients and their antibiotic resistance patterns.
ositive organism, n (%) No. Pen Amp Ox Van Ery CC FQ
ococcus spp. 4 2 (50.0) 0 (0.0) 3 (75.0) 2 (50.0) 2 (50.0)
ase-negative staphylococcus 5 4 (80.0) 2 (40.0) 0 (0.0) 3 (60.0) 1 (20.0) 2 (40.0)
spp. 1 0 (0.0)
lococcus aureus 1 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0) 1 (100.0) 1 (100.0)
lococcus saprophyticus 1 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0)
coccus feceium 1 1 (100.0) 1 (100.0)
egative
m, n (%)
No. Amp CF GM CAZ AMS TZP MP FQ FEP MDR
ichia 7 7 (100.0) 3 (42.8) 4 (57.1) 1 (14.2) 6 (85.7) 0 (0.0) (0.0) 7 (100.0) 1 (14.2) 6 (85.7)
lla
umonia
2 2 (100.0) 2 (100.0) 2 (100.0) 2 (100.0) 2 (100.0) 1 (50.0) (0.0) 2 (100.0) 2 (100.0) 2 (100.0)
ia
cescens
1 1 (100.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
obacter
soxidans
1 1 (100.0) 1 (100.0) 1 (100.0) 0 (0.0) (0.0) 1 (100.0) 1 (100.0) 1 (100.0)
obacter
mannii
1 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) (100.0) 1 (100.0) 1 (100.0) 1 (100.0)
bacter
cae
1 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0) 1 (100.0) 0 (0.0) (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
obacter
ffii
1 1 (100.0) 1 (100.0) 0 (0.0) 1 (100.0) 1 (100.0) 1 (100.0) (0.0) 1 (100.0) 1 (100.0) 1 (100.0)
bic bacteremia, n (%) No. Pen CC TZP METR
oides thetaiotaomicron 1 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
ampicillin; AMSZ ampicillin-sulbactam; CAZZ ceftazidime; CCZ clindamycin; CFZ cefazolin; CROZ ceftria thromycin; FEPZ cefepime; FQZ fluoroquinolone;
gentamycin; HSCT Z hematopoietic stem cell transplantation; IMP Z imipenum-cilastatin; MDR Z mu stance; METR Z metronidazole; Ox Z oxacillin;
penicillin; Tei Z teicoplanin; TZP Z piperacillin-tazobactam; Van Z vancomycin.
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Figure 1. In vitro antibiotic resistance rate of (A) Gram-
positive a and (B) Gram-negative blood isolates from hemato-
poietic stem cell transplantation recipients. a Enterococcus
and Rothia spp. were excluded for analysis. b Only staphylo-
coccus spp. was tested. Amp Z ampicillin; AMS Z ampicillin-
sulbactam; CAZ Z ceftazidime; CC Z clindamycin;
CF Z cefazolin; CRO Z ceftriaxone; Ery Z erythromycin;
FEP Z cefepime; FQ Z fluoroquinolone; GM Z gentamycin;
IMP Z imipenum-cilastatin; MDR Z multiple-drug resistance;
Ox Z oxacillin; Pen Z penicillin; Tei Z teicoplanin;
TZP Z piperacillin-tazobactam; Van Z vancomycin.
6 C.-H. Wang et al.
+ MODELBacteremia in allo- and autoeHSCT recipients
Table 1 summarizes the clinical characteristics of allo- and
autoeHSCT recipients with and without bacteremia. Eigh-
teen episodes of bacteremia occurred in 16 allo-HSCT re-
cipients, while 10 episodes occurred in 10 auto-HSCT
recipients. There were no episodes of post-neutrophil-
engraftment bacteremia in auto-HSCT recipients, while
two of the 55 allo-HSCT recipients (3.6%) experienced post-
neutrophil-engraftment bacteremia and had concomitant
Grade 3e4 acute graft-versus-host disease (GVHD). The
median bacteremia onset duration was 9.5 (range: 0e40)
and 9 (range: 4e11) days in allo-HSCT recipients and auto-
HSCT recipients, respectively, after transplantation. Among
allo-HSCT recipients with bacteremia (n Z 15), six (40%)
suffered from septic shock from bacteremia, with 33.3%
early mortality. In auto-HSCT recipients with bacteremia
(n Z 10), septic shock occurred in one patient (10%) at
bacteremia onset, with 10.0% early mortality.
Grade 3e4 GVHD in allo-HSCT recipients was associated
with bacteremia (40.0% vs. 2.5%, p Z 0.001), and longer
engraftment duration after transplantation was associatedPlease cite this article in press as: Wang C-H, et al., Characteristics
poietic stem cell-transplant recipients with levofloxacin prophylaxis
biology, Immunology and Infection (2016), http://dx.doi.org/10.1016/with bacteremia in auto-HSCT recipients (p Z 0.002).
Bacterial prophylaxis using a higher dose of levofloxacin
(750 mg/day) had no influence on the incidence of
bacteremia as compared with the lower dose (500 mg/day)
in allo- and auto-HSCT recipients (p > 0.99 and p Z 0.725,
respectively). Patients with bacteremia exhibited higher
early mortality relative to those without bacteremia (33.3%
vs. 12.5%, p Z 0.013). Auto-HSCT recipients with bacter-
emia showed no difference in mortality (p Z 0.363), but
had a longer hospital stay after transplantation as
compared with patients without bacteremia (25 days vs.
21 days, p Z 0.014).
Blood isolates from HSCT recipients.
Blood isolates from HSCT recipients and related antibio-
grams are summarized in Table 2 and Figure 1. Of the
28 bacterial isolates, 13 were Gram-positive, 14 were
Gram-negative, and one was anaerobic. The most common
Gram-positive blood isolates were coagulase-negative
Staphylococci, while Escherichia coli was the most
commonly isolated Gram-negative bacteria. All Gram-
negative bacteria were resistant to fluoroquinolone, and
most Gram-negative bacteria (92.8%) were also multiple-
drug resistant.
Discussion
Our study revealed that bacteremia accounted for the
majority of early mortality in HSCT recipients after trans-
plantation. The risk factors and clinical outcomes of
bacteremia between allo- and auto-HSCT recipients were
different, despite receiving identical supportive care and
prophylactic antibiotics. Additionally, we observed emer-
gence of fluoroquinolone-resistant and multiple-drug
resistant Gram-negative bacteria in both allo- and auto-
HSCT recipients after levofloxacin use.
In auto-HSCT recipients, longer durations of neutropenia
were associated with the occurrence of bacteremia. This
result was consistent with results from previous
studies.7,28,29 Reducing the duration of neutropenia may,
therefore, help decrease the incidence of bacteremia.
Peripheral-blood stem cell transplants and use of growth
factors in auto-HSCT recipients were reported to shorten
the duration of neutropenia and were routinely used in our
transplantation protocol.29,30
Previous reports showed that the severity of mucositis
was associated with bacteremia and reduced survival.31,32
Current oral hygiene measures in our protocols included
daily gargling with a chlorhexidine gluconate solution only
during the peritransplantation period. Recently, a new
agent, palifermins, which is a keratinocyte growth factor,
was approved by the Food and Drug Administration to
reduce the severity of mucositis in auto-HSCT recipients
after chemotherapy. However, its clinical efficacy in
improving infectious complications and overall survival
remain uncertain.33,34 The use of this new agent in HSCT
recipients may be another way to decrease bacteremia and
improve outcomes.
In allo-HSCT recipients, acute GVHD Grade 3e4 was
associated with bacteremia, but the relationship wascomparisons of bacteremia in allogeneic and autologous hemato-
and influence on resistant bacteria emergence, Journal of Micro-
j.jmii.2016.02.003
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bacteremia: bacteria traversed the breaks in mucosa of the
oral cavity and gastrointestinal tract, resulting in bacter-
emia.35,36 Most cases of bacteremia in our study, however,
occurred during the neutropenic phase when GVHD had not
yet occurred. A possible explanation is that cytokines
released during bacteremia in the pre-engraftment period
precipitated the subsequent occurrence of GVHD.37,38 When
acute GVHD occurred in allo-HSCT recipients it was associ-
ated with subsequent invasive fungal infections and a risk of
increasedmortality.39 To prevent acute GVHD and infectious
complications in allo-HSCT recipients, pre-engraftment
reduction in bacteremia is an important step. However,
there were no other risk factors identified in allo-HSCT re-
cipients in our study, possibly because of the limited number
of cases included. Our study showed that bacteremia was
associated with increased morbidity in auto-HSCT recipients
and increased mortality in allo-HSCT recipients. This obser-
vation was in agreement with those of prior studies showing
that bacteremia had a more deleterious effect on allo-HSCT
recipients relative to auto-HSCT recipients.7,16,40
Past studies on risk factors and outcomes of bacteremia
in HSCT recipients were carried out in either auto- or allo-
HSCT recipients. Our study compared the differences in
characteristics and outcomes of bacteremia between allo-
and auto-HSCT recipients and revealed several differences,
despite identical supportive cases and prophylactic antibi-
otics used in agreement with previous studies.35 Using
different strategies to reduce bacteremia in allo- and auto-
HSCT recipients tailored to their respective characteristics
may be more cost effective than current universal pro-
phylactic measures.
There are no previous studies that compared the clinical
benefits of different doses of levofloxacin for prophylaxis in
HSCT recipients. The results of our study suggested that a
higher dose of levofloxacin for prophylaxis had no addi-
tional effect on the prevention of bacteremia. Since this
study was retrospective in nature, rather than randomized
and prospective, the results should be interpreted with
caution. Additionally, suggested use of empirical antibi-
otics, including antipseudo penicillium, ceftazidime, and
cefepime, in patients with neutropenic fever did not show
promising antibacterial activity, except for carbapenem, in
our study.20 Breakthrough bacteremia involving Gram-
negative bacteria was fluoroquinolone-resistant and, in
most cases, also multiple-drug resistant. Our study results
were in agreement with those of other studies from Taiwan
that reported that fluoroquinolone prophylaxis in HSCT
recipients may result in the development of
fluoroquinolone-resistant and multiple-drug resistant
bacteremia.16,18 Due to the small sample size of this study,
more epidemiologic data from Taiwan on bacteria isolated
from HSCT recipients and continuous surveillance are
required in order to guide clinicians regarding optimal
empirical antibiotic use.
There were a few limitations in our study. This study was
retrospective in nature, and changes in daily care that were
not recorded in the medical charts may have led to con-
founding of the data. Definitions of bacterial infections
other than bacteremia according to the Centers for Disease
Control may not apply to our patients, because most were
neutropenic when sepsis occurred and had few clinicalPlease cite this article in press as: Wang C-H, et al., Characteristics
poietic stem cell-transplant recipients with levofloxacin prophylaxis a
biology, Immunology and Infection (2016), http://dx.doi.org/10.1016/symptoms. In this circumstance, therefore, the number of
patients with bacterial infections may have been under-
estimated. Only a limited number of blood isolates were
collected for analysis in this study; therefore, it is difficult
to make a definitive conclusion on changes in the pattern of
antibiotic resistance in HSCT recipients. Finally, the sample
sizes of our two groups were relatively small, which may
explain why some findings may not have reached statistical
significance.
Conclusion
In conclusion, our study revealed that allo- and auto-HSCT
recipients had different clinical features and outcomes.
These differences should be taken into account when
designing strategies to reduce the incidence of bacter-
emia in allo- and auto-HSCT recipients. There was also
evidence of fluoroquinolone resistance and multiple-drug
resistance in Gram-negative bacteria after the use of
levofloxacin. It is therefore crucial to monitor changes in
the patterns of antibiotic resistance in blood isolates from
HSCT recipients.
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